These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35701983)

  • 1. FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.
    Guo L; Wu Z
    Neuropathology; 2022 Oct; 42(5):430-446. PubMed ID: 35701983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
    Li C; Feng S; Chen L
    Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
    Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
    Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway.
    Yin H; Cui X
    Cancer Biother Radiopharm; 2021 Sep; 36(7):556-567. PubMed ID: 32833501
    [No Abstract]   [Full Text] [Related]  

  • 6. Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
    Ding C; Yi X; Chen X; Wu Z; You H; Chen X; Zhang G; Sun Y; Bu X; Wu X; Lin Z; Gu J; Lin Y; Kang D
    J Exp Clin Cancer Res; 2021 May; 40(1):164. PubMed ID: 33975615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.
    Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W
    J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
    Jiang C; Shen F; Du J; Fang X; Li X; Su J; Wang X; Huang X; Liu Z
    Biomed Pharmacother; 2018 Jan; 97():844-850. PubMed ID: 29136760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM).
    He Z; Cheng M; Hu J; Liu L; Liu P; Chen L; Cao D; Tang J
    J Transl Med; 2022 Oct; 20(1):443. PubMed ID: 36183123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomal circ-HIPK3 Facilitates Tumor Progression and Temozolomide Resistance by Regulating miR-421/
    Han C; Wang S; Wang H; Zhang J
    Cancer Biother Radiopharm; 2021 Sep; 36(7):537-548. PubMed ID: 32644821
    [No Abstract]   [Full Text] [Related]  

  • 12. Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway.
    Zhang P; Chen XB; Ding BQ; Liu HL; He T
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30455394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
    Hu YH; Jiao BH; Wang CY; Wu JL
    CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
    Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
    BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
    Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
    Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
    [No Abstract]   [Full Text] [Related]  

  • 16. FoxM1-mediated RFC5 expression promotes temozolomide resistance.
    Peng WX; Han X; Zhang CL; Ge L; Du FY; Jin J; Gong AH
    Cell Biol Toxicol; 2017 Dec; 33(6):527-537. PubMed ID: 28185110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
    Kong S; Cao Y; Li X; Li Z; Xin Y; Meng Y
    J Cell Mol Med; 2020 Apr; 24(8):4677-4686. PubMed ID: 32181582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis.
    Wei Y; Duan S; Gong F; Li Q
    Biochem Biophys Res Commun; 2022 May; 603():153-159. PubMed ID: 35294905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.
    Li H; Liu Q; Chen Z; Wu M; Zhang C; Su J; Li Y; Zhang C
    Cell Death Dis; 2021 Mar; 12(3):252. PubMed ID: 33674567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.